References:
1. Ansell SM, Grant CS, Habermann TM. Primary thyroid lymphoma. Seminars in oncology. 1999;26(3):316-23.
2. Stein SA, Wartofsky L. Primary thyroid lymphoma: a clinical review. J Clin Endocrinol Metab. 2013;98(8):3131-8.
3. Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL. Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol. 2000;24(5):623-39.
4. Widder S, Pasieka JL. Primary thyroid lymphomas. Curr Treat Options Oncol. 2004;5(4):307-13.
5. Graff-Baker A, Roman SA, Thomas DC, Udelsman R, Sosa JA. Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases. Surgery. 2009;146(6):1105-15.
6. Travaglino A, Pace M, Varricchio S, Insabato L, Giordano C, Picardi M, et al. Hashimoto Thyroiditis in Primary Thyroid Non-Hodgkin Lymphoma. Am J Clin Pathol. 2020;153(2):156-64.
7. Kossev P, Livolsi V. Lymphoid lesions of the thyroid: review in light of the revised European-American lymphoma classification and upcoming World Health Organization classification. Thyroid : official journal of the American Thyroid Association. 1999;9(12):1273-80.
8. Moshynska OV, Saxena A. Clonal relationship between Hashimoto thyroiditis and thyroid lymphoma. J Clin Pathol. 2008;61(4):438-44.
9. Sakorafas GH, Kokkoris P, Farley DR. Primary thyroid lymphoma (correction of lympoma): diagnostic and therapeutic dilemmas. Surg Oncol. 2010;19(4):e124-9.
10. Zhang L, Castellana M, Virili C, Crescenzi A, Giorgino F, Zucca E, et al. Fine-needle aspiration to diagnose primary thyroid lymphomas: a systematic review and meta-analysis. Eur J Endocrinol. 2019;180(3):177-87.
11. Graff-Baker A, Sosa JA, Roman SA. Primary thyroid lymphoma: a review of recent developments in diagnosis and histology-driven treatment. Curr Opin Oncol. 2010;22(1):17-22.
12. Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Crit Rev Oncol Hematol. 2020;150:102972.
13. Weinkove R, McQuilten ZK, Adler J, Agar MR, Blyth E, Cheng AC, et al. Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Med J Aust. 2020;212(10):481-9.
14. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-7.
15. Doria R, Jekel JF, Cooper DL. Thyroid lymphoma. The case for combined modality therapy. Cancer. 1994;73(1):200-6.
16. Mian M, Gaidano G, Conconi A, Tsang R, Gospodarowicz MK, Rambaldi A, et al. High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. Leuk Lymphoma. 2011;52(5):823-32.
17. Onal C, Li YX, Miller RC, Poortmans P, Constantinou N, Weber DC, et al. Treatment results and prognostic factors in primary thyroid lymphoma patients: a rare cancer network study. Ann Oncol. 2011;22(1):156-64.
18. Peixoto R, Correia Pinto J, Soares V, Koch P, Taveira Gomes A. Primary thyroid lymphoma: A case report and review of the literature. Ann Med Surg (Lond). 2017;13:29-33.
19. Mack LA, Pasieka JL. An evidence-based approach to the treatment of thyroid lymphoma. World J Surg. 2007;31(5):978-86.
20. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105-16.
21. Tupchong L, Hughes F, Harmer CL. Primary lymphoma of the thyroid: clinical features, prognostic factors, and results of treatment. Int J Radiat Oncol Biol Phys. 1986;12(10):1813-21.